The difference between information and
expert, data-driven actionable intelligence
Welcome to the February 2016 issue of CMC Market Outlook
This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.
Enjoy the February issue!
by Jim Miller, President, PharmSource
Bio/pharmaceutical companies, and the companies that serve them, tend to think they are immune from broader macroeconomic and political developments. As populations age, emerging middle classes expand, and scientific knowledge progresses, research on new drugs and demand for new therapies seem to follow an inexorably upward trend.
However, the global financial crisis of 2008 demonstrated that the industry is not isolated from macro events. Early-stage companies, which drive the early development engine, had great difficulty raising money as the availability of… read on
Charles River Acquires WIL Research, May Target CTM Manufacture
Charles River Laboratories (CRL) is acquiring preclinical CRO WIL Research Laboratories for $585 million. CRL pegged the acquisition price at a multiple of 12.9x adjusted EBITDA, and will finance the deal with debt. The transaction is expected to close in the second quarter of this year.
The acquisition of WIL Research gives CRL additional capacity in safety assessment (toxicology) services, an area where there is strong demand because of all of the funding for early stage pipeline and companies. That includes… read on
Contract Manufacturing Market Opportunities for Antibody Drug Conjugates
PharmSource’s just-released report, ADC Market Opportunity for CMOs, is an indispensable resource for understanding the technical developments in the antibody drug conjugate (ADC) sector and the scale of the commercial opportunities and risks for CMOs.
The CDMO sector is investing significant resources to expand its capabilities in the ADC arena. More than 20 companies are active in the sector although, to date, no single company… click here
Process Technology Feature added to Strategic Advantage database
PharmSource Strategic Advantage subscribers can now search for biologics in the products database based on their processing technology. A new searchable field, “API Process Technology,” allows users to search for biologics products based on whether they were manufactured using mammalian cell culture, microbial fermentation or other expression technologies. This can be especially useful for biopharma companies looking for CMOs that have a track record of making commercially-approved products using a particular technology.
For questions about this feature or any other inquiries, please contact our Director of Account Management, Blythe Moore, at +1.703.383.4903, ext. 104 | email@example.com.
DCAT Week 2016
Pharmaceutical Outsourcing CMO Outlook
PharmSource president Jim Miller will give an overview of the contract dose market for solid dosage and sterile drug products, including key trends, capacity utilization and strategies for supplier differentiation at the Pharmaceutical Outsourcing program on Tuesday, March 15 in the Waldorf Astoria’s Empire Room.
Join us for DCAT’s 2016 Pharma Industry Outlook
PharmSource is also pleased to be the program partner for the 2016 Pharma Industry Outlook session, which will be held Monday, March 14 at 1:15 pm in the Waldorf Astoria’s Empire Room. The pharmaceutical industry has experienced favorable signs, a rebound in US pharmaceutical growth and new product innovation. Find out how sustainable these trends are and what role emerging markets will play.
PharmSource Strategic Advantage
PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.
See for yourself how this resource gives you vital tools for understanding the industry.
To request a test-drive today, contact Nathaniel Celentano at firstname.lastname@example.org / +1-703-383-4903, ext. 112 (ET USA).